Respiratory syncytial virus and other respiratory virus infections in residents of homeless shelters - King County, Washington, 2019-2021.
homeless youth
human
ill‐housed persons
influenza
respiratory syncytial virus infections
respiratory syncytial viruses
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
27
03
2023
revised:
26
05
2023
accepted:
27
05
2023
medline:
26
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
Respiratory syncytial virus (RSV) causes disproportionate morbidity and mortality in vulnerable populations. We tested residents of homeless shelters in Seattle, Washington for RSV in a repeated cross-sectional study as part of community surveillance for respiratory viruses. Of 15 364 specimens tested, 35 had RSV detected, compared to 77 with influenza. The most common symptoms for both RSV and influenza were cough and rhinorrhea. Many individuals with RSV (39%) and influenza (58%) reported that their illness significantly impacted their ability to perform their regular activities. RSV and influenza demonstrated similar clinical presentations and burden of illness in vulnerable populations living in congregate settings.
Identifiants
pubmed: 37346095
doi: 10.1111/irv.13166
pii: IRV13166
pmc: PMC10279995
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13166Informations de copyright
© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
Dr. E. Chow reported honoraria from Providence Health & Services, Renton, Washington for presentations on COVID‐19. Dr. P. Roychoudhury reported honoraria from The Bill & Melinda Gates Foundation and Association for Molecular Pathology for presentations on COVID‐19. Dr. M. Boeckh reported consulting with GlaxoSmithKline and Janssen and has received research support from Janssen, outside the submitted work. Dr. A. Greninger reports contract testing from Abbott and research support from Gilead and Merck. Dr. J. Englund reported consulting with Sanofi Pasteur, AstraZeneca, and Meissa Vaccines, and has received research funding from AstraZeneca, GlaxoSmithKline, Merck, and Pfizer outside the submitted work. Dr. H. Chu reported consulting with Ellume, Pfizer, The Bill and Melinda Gates Foundation, Glaxo Smith Kline, Abbvie, and Merck. She has received research funding from Gates Ventures, Sanofi Pasteur, and support and reagents from Ellume and Cepheid outside of the submitted work. All other authors report no conflicts of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Références
Am J Prev Med. 2010 Aug;39(2):164-72
pubmed: 20621264
N Engl J Med. 2020 Jul 9;383(2):185-187
pubmed: 32356944
Emerg Infect Dis. 2019 Jul;25(7):1408-1411
pubmed: 31211675
Clin Microbiol Infect. 2021 Oct;27(10):1520.e1-1520.e5
pubmed: 34111590
Clin Chem. 2020 Jul 1;66(7):966-972
pubmed: 32379863
JAMA Netw Open. 2021 Mar 1;4(3):e210490
pubmed: 33651111
J Clin Microbiol. 2016 Dec 28;55(1):177-182
pubmed: 27795347
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Clin Infect Dis. 2021 Jul 1;73(1):e158-e163
pubmed: 32531019
Influenza Other Respir Viruses. 2023 Jan;17(1):e13092
pubmed: 36610058
BMJ Open. 2020 Oct 7;10(10):e037295
pubmed: 33033018
Clin Infect Dis. 2021 Dec 6;73(11):e4411-e4418
pubmed: 33197930
South Med J. 2010 Jan;103(1):18-24
pubmed: 19996848
Chest. 2004 May;125(5):1719-25
pubmed: 15136382